Wegovy vs Mounjaro Tracker App: What Actually Changes When You Switch
5 min read
CEO & Co-Founder of miora. Consumer health growth expert.
Wegovy and Mounjaro both work in the GLP-1 family but they are not the same compound. Semaglutide is a pure GLP-1 agonist; tirzepatide is dual GIP/GLP-1. The side-effect curves, titration paces, and the things worth being most attentive to differ in ways the marketing does not surface. This guide walks the tracker setup for both, what changes if you switch, and how miora handles the switch in iMessage.
Topics on this page
Semaglutide and tirzepatide are different compounds, not the same molecule under different labels. The mechanism, titration, and side-effect profile differ in meaningful ways.
The titration schedules differ: Wegovy has five steps (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg); Mounjaro has six (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg). The mapping between dose levels is approximate, not exact.
Side-effect curves differ slightly. Semaglutide tends to peak day 2-3 post-injection; tirzepatide tends to peak day 1-2. The day-relative log captures the difference.
The most common scenario for switching between Wegovy and Mounjaro is insurance coverage. Plans change formularies quarterly. A user on Wegovy 1.7 mg gets a notice that Mounjaro is now covered and Wegovy is not, or the reverse. The compounds are not interchangeable - they are different molecules - but the prescribers handle the switch routinely and the user is expected to adjust the protocol accordingly. The tracker should make that switch smooth, not noisy. This is the comparison of what stays the same and what changes when the compound changes.
Semaglutide is a glucagon-like peptide-1 receptor agonist. It binds the GLP-1 receptor and produces the appetite-suppression and glycemic effects characteristic of the class. Tirzepatide is a dual agonist - it binds both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. The GIP component is what produces some of the additional weight-loss and metabolic effects beyond what semaglutide produces.
For tracking purposes, two practical consequences. First, the side-effect profiles differ. Pure GLP-1 agonism (semaglutide) tends to produce a relatively defined nausea curve that peaks day 2-3 after the injection. Dual GIP/GLP-1 (tirzepatide) tends to produce a slightly faster peak (day 1-2) with more variability in fatigue and a different GI signature. Neither is better or worse; they are different curves and the daily log captures the actual shape for the individual user.
Second, the dose-response curves differ. Tirzepatide's dose-response is steeper in the upper steps - the jump from 10 mg to 15 mg is more meaningful clinically than the jump from 1.7 mg to 2.4 mg on semaglutide for many users. This shows up in the smoothed weight trend and the side-effect curve simultaneously.
The standard FDA-approved titration schedules:
Wegovy (semaglutide). Five steps, each 4 weeks: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg. Total titration time to maintenance dose is approximately 16-20 weeks. Many users stay at 1.7 mg as a maintenance dose if the response is adequate and the side-effect curve at 2.4 mg is not tolerated.
Mounjaro / Zepbound (tirzepatide). Six steps, each 4 weeks: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg. Total titration time is approximately 20-24 weeks. The 5 mg and 10 mg steps are common maintenance doses; the 15 mg is the ceiling.
The dose-level mapping between the two compounds is approximate. The clinical literature suggests something like semaglutide 1.0 mg ≈ tirzepatide 5 mg for many users, and semaglutide 2.4 mg ≈ tirzepatide 10 mg, but individual response varies and the analogy is rough. A switch should be a clinician-managed dose decision, not a community-protocol decision.
Mapped to days post-injection, the typical curves look like this in the daily log.
Semaglutide (Wegovy). Day 0: injection. Day 1: mild nausea onset. Day 2: peak nausea, often a 3 or 4 out of 5. Day 3: nausea still elevated, energy dip arriving. Day 4: recovery starting. Day 5: near baseline. Day 6: baseline. The peak is later and the curve is broader than tirzepatide.
Tirzepatide (Mounjaro/Zepbound). Day 0: injection. Day 1: faster nausea onset, peak often day 1 or 2. Day 2: nausea still high but fatigue arriving. Day 3: recovery starting earlier than semaglutide. Day 4-6: baseline. The peak is earlier and the curve is narrower but fatigue can be more variable.
These are population averages. The individual curve is what the daily log captures, and it can differ substantially from the average. A user with the opposite shape - semaglutide with a faster peak or tirzepatide with a broader curve - is not abnormal; the individual curve is the operative data.
Two compound-specific attention points worth knowing.
On Wegovy (semaglutide). Mood drift appears to surface slightly earlier in the community reports. Week 8 to 12 is where the anhedonia and flat-affect signals start showing up in the long Reddit threads. The six-dimension mood rubric becomes the operative tracking layer from week 8 onward on semaglutide. The mood rubric guide has the full detail.
On Mounjaro (tirzepatide). Fatigue variability is the more notable signal. Some users have very flat energy curves; some have dramatic day-2 to day-3 dips. The fatigue pattern often correlates with hydration and training-load amplifiers more than it does with the dose itself. Hydration in ounces becomes the operative daily metric on tirzepatide.
Both compounds: protein intake in grams is the most-missed daily metric, and resistance training plus adequate protein is the muscle-preservation protocol. The muscle-preservation guide applies identically across both compounds.
Switching from one compound to the other is a clinician decision and is usually driven by insurance. The clinical handoff varies; some prescribers start the new compound at a step that approximates the previous compound's maintenance dose, some restart at a lower step to confirm tolerance, some pause briefly between.
For tracking, the right approach is to treat the switch as a continuation. The cycle history, side-effect baseline, mood baseline, weight trend, and protein-and-hydration logs all carry forward. The new compound is logged with its own dose schedule but the baseline data from the previous compound is the comparison.
The first 4-6 weeks on the new compound are the calibration period. The side-effect curve at the new compound's maintenance dose may differ from the previous compound's curve at its maintenance dose. miora's weekly summary during this period explicitly references the previous compound's data so the comparison is structural rather than verbal.
The miora workflow for a Wegovy-to-Mounjaro or Mounjaro-to-Wegovy switch is straightforward.
Day of switch. The new compound, dose step, and start date are logged. The previous compound is closed out (final dose date noted). The daily check format does not change.
First 4 weeks on new compound. Weekly summary references the previous compound's curve at its closest dose step. Differences in nausea timing, fatigue pattern, GI signature, and mood are surfaced explicitly.
Ongoing. The new compound's data accumulates and becomes the operative baseline. Previous-compound data remains in the log as historical context.
If the switch produces a worse side-effect profile or worse outcome trend, miora surfaces that in the weekly summary. The decision to switch back, adjust dose, or stay belongs with the prescriber.
Most GLP-1 tracker apps are built around one compound and have to be re-configured for the other. A few are compound-agnostic. The criteria for a tool that handles both well:
Handles both titration schedules. Wegovy's 5 steps and Mounjaro's 6 steps, with the correct intervals and dose values pre-configured.
Day-relative side-effect log. Mapping to days post-injection, not just dates. This is what makes the curve comparison work across compounds.
Treats a switch as a continuation. Baseline carries forward; comparison logic adjusts for the compound difference.
Six-dimension mood rubric. Catches the mood drift signal independent of which compound.
Protein and hydration in the daily log. The two most-missed metrics, applicable to both compounds.
Smoothed weight trend. 14-day moving average, not raw daily.
Private storage and on-demand export. Same standard regardless of compound.
miora was built around these criteria specifically. The compound-agnostic structure is what makes mid-protocol switches clean.
Three boundaries.
This guide does not recommend either compound. Wegovy and Mounjaro are both FDA-approved for weight management (Zepbound is the equivalent tirzepatide product specifically branded for weight loss). The choice between them - or between them and any other GLP-1 - is a clinician decision based on coverage, response history, side-effect tolerance, and clinical judgment.
The guide does not promise that switching will produce a specific outcome. Some users have a better response on one compound than the other; some have similar responses; some find one easier to tolerate. Individual response is individual.
The guide does not recommend dose mapping between compounds. The approximate dose equivalencies discussed here are rough; the specific dose on a switch is a prescriber decision. This content is for informational purposes only and is not medical advice. Both Wegovy and Mounjaro require prescription and clinician supervision.
102
